Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer CEO Dr. Albert Bourla speaks to CNN’s Meg Tirrell about pushing past vaccine skepticism to work with the Trump ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...